Novel Immunosuppression: R348, a JAK3- and Syk-Inhibitor Attenuates Acute Cardiac Allograft Rejection
Deuse T, Velotta J, Hoyt G, Govaert J, Taylor V, Masuda E, Herlaar E, Park G, Carroll D, Pelletier M, Robbins R, Schrepfer S. Novel Immunosuppression: R348, a JAK3- and Syk-Inhibitor Attenuates Acute Cardiac Allograft Rejection. Transplantation 2008, 85: 885-892. PMID: 18360272, DOI: 10.1097/tp.0b013e318166acc4.Peer-Reviewed Original ResearchConceptsCombination regimensAllograft survivalAcute cardiac allograft rejectionPrevention of acute rejectionCardiac allograft survivalCardiac allograft rejectionPostoperative day 5Th2 immune responseInflammatory cytokine upregulationAnimals treated with different dosesEnzyme-linked immunosorbent assayEvaluate drug interactionsGraft infiltrationAcute rejectionAllograft rejectionGraft functionInhibition of JAK3Immune cellsPlasma levelsCytokine upregulationTacrolimusDrug interactionsPharmacokinetic dataCellular Th1Treatment period
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply